| A view on drug resistance in cancer N Vasan, J Baselga, DM Hyman Nature 575 (7782), 299-309, 2019 | 2234 | 2019 |
| The genomic landscape of endocrine-resistant advanced breast cancers P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ... Cancer cell 34 (3), 427-438. e6, 2018 | 905 | 2018 |
| An atlas of substrate specificities for the human serine/threonine kinome JL Johnson, TM Yaron, EM Huntsman, A Kerelsky, J Song, A Regev, ... Nature 613 (7945), 759-766, 2023 | 347 | 2023 |
| Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors N Vasan, P Razavi, JL Johnson, H Shao, H Shah, A Antoine, E Ladewig, ... Science 366 (6466), 714-723, 2019 | 264 | 2019 |
| Metastasis and immune evasion from extracellular cGAMP hydrolysis J Li, MA Duran, N Dhanota, WK Chatila, SE Bettigole, J Kwon, RK Sriram, ... Cancer discovery 11 (5), 1212-1227, 2021 | 219 | 2021 |
| Dietary fructose improves intestinal cell survival and nutrient absorption SR Taylor, S Ramsamooj, RJ Liang, A Katti, R Pozovskiy, N Vasan, ... Nature 597 (7875), 263-267, 2021 | 211 | 2021 |
| Overview of the relevance of PI3K pathway in HR-positive breast cancer N Vasan, E Toska, M Scaltriti Annals of oncology 30, x3-x11, 2019 | 155 | 2019 |
| Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors P Razavi, MN Dickler, PD Shah, W Toy, DN Brown, HH Won, BT Li, ... Nature Cancer 1 (4), 382-393, 2020 | 141 | 2020 |
| A RAS renaissance: emerging targeted therapies for KRAS-mutated non–small cell lung cancer N Vasan, JL Boyer, RS Herbst Clinical cancer research 20 (15), 3921-3930, 2014 | 127 | 2014 |
| At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy N Vasan, LC Cantley Nature Reviews Clinical Oncology 19 (7), 471-485, 2022 | 105 | 2022 |
| A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for … N Vasan, R Yelensky, K Wang, S Moulder, H Dzimitrowicz, R Avritscher, ... The oncologist 19 (5), 453-458, 2014 | 63 | 2014 |
| TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors E Cocco, JE Lee, S Kannan, AM Schram, HH Won, S Shifman, A Kulick, ... Cancer discovery 11 (1), 126-141, 2021 | 47 | 2021 |
| Phase and context shape the function of composite oncogenic mutations AN Gorelick, FJ Sánchez-Rivera, Y Cai, CM Bielski, E Biederstedt, ... Nature 582 (7810), 100-103, 2020 | 47 | 2020 |
| Structure of a C-terminal fragment of its Vps53 subunit suggests similarity of Golgi-associated retrograde protein (GARP) complex to a family of tethering complexes N Vasan, A Hutagalung, P Novick, KM Reinisch Proceedings of the National Academy of Sciences 107 (32), 14176-14181, 2010 | 44 | 2010 |
| The intrinsic substrate specificity of the human tyrosine kinome TM Yaron-Barir, BA Joughin, EM Huntsman, A Kerelsky, DM Cizin, ... Nature, 1-8, 2024 | 33 | 2024 |
| The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity P Ho, JC Melms, M Rogava, CJ Frangieh, J Poźniak, SB Shah, Z Walsh, ... Cancer cell 41 (7), 1207-1221. e12, 2023 | 30 | 2023 |
| Treating alpelisib-induced hyperglycemia with very low carbohydrate diets and sodium-glucose co-transporter 2 inhibitors: a case series T Blow, PN Hyde, JN Falcone, A Neinstein, N Vasan, R Chitkara, MA Hurd, ... Integrative cancer therapies 20, 15347354211032283, 2021 | 21 | 2021 |
| Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations S Sivakumar, DX Jin, R Rathod, J Ross, LC Cantley, M Scaltriti, JW Chen, ... Clinical Cancer Research 29 (6), 1125-1136, 2023 | 14 | 2023 |
| A global atlas of substrate specificities for the human serine/threonine kinome JL Johnson, TM Yaron, EM Huntsman, A Kerelsky, J Song, A Regev, ... BioRxiv, 2022.05. 22.492882, 2022 | 12 | 2022 |
| The CD58: CD2 axis is co-regulated with PD-L1 via CMTM6 and governs anti-tumor immunity P Ho, JC Melms, M Rogava, CJ Frangieh, SB Shah, Z Walsh, O Kyrysyuk, ... BioRxiv, 2022.03. 21.485049, 2022 | 7 | 2022 |
Maurizio ScaltritiAstraZenecaastrazeneca.com의 이메일 확인됨